PeopleBeatingCancer

Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission

Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.

Click the orange button to the right to learn more about what you can start doing today.

Learn More

Myeloma Kidney Protection

Share Button

Myeloma kidney protection is essential. I say this because, according to research, about half of all newly diagnosed MM patients have kidney involvement. 

Unfortunately, many of the standard MM therapies for MM patients can negatively affect kidney function.

Which common therapies used to treat multiple myeloma can negatively affect kidney function?

1. Chemotherapy

  • Drugs like cisplatin and cyclophosphamide: These can be nephrotoxic and may cause direct kidney injury, especially in patients with preexisting kidney impairment.
  • Mitigation: Hydration protocols and dose adjustments are often necessary.

2. Immunomodulatory Drugs (IMiDs)

  • Lenalidomide and pomalidomide: While effective, these drugs can sometimes worsen kidney function, particularly in patients with baseline kidney disease. Dose adjustments are essential based on kidney function.

3. Proteasome Inhibitors

  • Bortezomib and carfilzomib: These drugs are generally kidney-safe and even beneficial for treating multiple myeloma-related kidney impairment. However, carfilzomib has been associated with cases of acute kidney injury (AKI), especially in patients with underlying risk factors.

4. Bisphosphonates

  • Pamidronate and zoledronic acid: These drugs, used to treat bone disease in multiple myeloma, can cause kidney toxicity, including acute tubular necrosis and glomerular injury, particularly if administered too frequently or at high doses.
  • Mitigation: Dose adjustments and careful monitoring are critical.

5. Monoclonal Antibodies

  • Daratumumab and isatuximab: These are less likely to directly harm the kidneys but can still complicate kidney function indirectly by causing immune-mediated effects or hypersensitivity reactions.

6. Radiotherapy

  • Radiation targeting areas near the kidneys can potentially cause kidney damage, although this is rare and depends on the dosage and targeting.

7. High-Dose Steroids

  • Dexamethasone or prednisone: While essential in multiple myeloma regimens, these can lead to fluid retention and hypertension, potentially exacerbating kidney issues.

8. Contrast Agents

  • Contrast dyes used during diagnostic procedures can cause contrast-induced nephropathy (CIN) in patients with compromised kidney function.

9. Stem Cell Transplantation

  • Conditioning regimens used before autologous stem cell transplants may involve nephrotoxic agents, such as high-dose melphalan.

In preparation for my stem cell collection, I underwent two rounds of high-dose cytoxan therapy. I was told that cytoxan would spur my body’s production of stem cells.

It is rare for conventional oncology to recommend a therapy that is not FDA approved. When I “failed” off the FDA approved conventional MM treatments and was told I was end-stage, I learned about non-conventional therapies such as omega-3 fatty acids.

Email me with questions about kidney health- David.PeopleBeatingCancer@gmail.com

Thank you,

David Emerson

  • MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

Omega-3 polyunsaturated fatty acids protect against cisplatin-induced nephrotoxicity by activating the Nrf2 signaling pathway

Highlights

  • Omega-3 PUFAs protect against cisplatin-induced nephrotoxicity.
  • Omega-3 PUFAs enhance the expression of antioxidant genes by activating the p62-Keap1-Nrf2 signaling pathway.
  • Omega-3 PUFAs inhibit cisplatin-induced apoptosis through the Nrf2-MDM2-p53 signaling pathway.
  • Omega-3 PUFAs protect against cisplatin-induced chronic kidney disease.

Nephrotoxicity is a prevalent side effect observed in patients undergoing chemotherapy. The pathogenesis of chemotherapy-induced nephrotoxicity involves various factors such as

  • oxidative stress,
  • DNA damage,
  • inflammation,
  • and apoptosis.

Omega-3 polyunsaturated fatty acids (ω-3 PUFAs), particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), possess anti-inflammatory and antioxidant properties.

This study investigated the effects of EPA and DHA, either alone or in combination, on cisplatin-induced nephrotoxicity in mice, as well as their underlying mechanisms of action. The combined administration of EPA and DHA demonstrated superior efficacy in mitigating cisplatin-induced nephrotoxicity compared to administration alone, including the reduction of oxidative damage, inflammation, and apoptosis.

Moreover, the combination of EPA and DHA suppressed inflammation and prevented the development of chronic kidney fibrosis during prolonged observations following repeated cisplatin administration. Mechanistically, ω-3 PUFAs enhance the expression of antioxidant genes by activating the p62-Keap1-Nrf2 signaling pathway. Furthermore, Nrf2 activation can inhibit the cisplatin-induced p53 apoptosis signal by upregulating the expression of MDM2 in renal tubular epithelial cells.

Consequently, ω-3 PUFAs exert a protective effect against cisplatin-induced renal injury through activating the Nrf2 signaling pathway, suggesting that ω-3 PUFAs intake holds promise as a therapeutic strategy for combating cisplatin-induced nephrotoxicity.”

 

Leave a Comment:

Popular posts

Multiple Myeloma Diet
 Multiple Myeloma Multiple Myeloma Diet
Feb 15, 2022
Multiple Myeloma Survivor- A Different kind of Second Opinion-
 Multiple Myeloma
Nov 04, 2022
C-B-D Enhances Velcade (BORT)
 integrative therapy Multiple Myeloma
Aug 07, 2022
Are Endometrial Polyps Overtreated?
 non-conventional therapies side effects ID and prevention
Nov 14, 2021